Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed endometrial cancer * Advanced or recurrent disease * Stage IIIB or IIIC disease * Stage IIIA disease allowed provided there is serosal involvement or direct extension or metastasis to the adnexa * No stage IIIA confirmed by only positive peritoneal washings * Stage IVA or IVB disease * Failed local therapy or considered incurable with local therapy * Measurable or evaluable disease * Not required for newly diagnosed stage III or IV disease with no remaining disease after surgery * Performance status Gynecology Oncology Group (GOG) 0-1 * Life expectancy at least 12 weeks * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL * Meets 1 of the following criteria: * Alkaline phosphatase (AP) normal AND aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST or ALT normal * Bilirubin normal * No acute hepatitis * Creatinine ≤ 1.5 mg/dL Exclusion Criteria: * Known hypersensitivity to docetaxel or polysorbate 80 * Severe infection * Septicemia * Pregnant or nursing * Positive pregnancy test * Fertile patients must use effective nonhormonal contraception during and for at least 3 months after study treatment * Peripheral neuropathy ≥ grade 2 * Severe gastrointestinal bleeding requiring a blood transfusion or hospitalization * Other malignancy within the past 5 years except nonmetastatic, nonmelanoma skin cancer or carcinoma in situ of the cervix * Prior chemotherapy * Prior radiotherapy